CA
NZ
UK
AU
IND
US
…
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary drug-delivery technologies and novel formulations aimed at addressing unmet therapeutic needs. Long-term growth may be supported by clinical progress across its pipeline, licensing or partnerships that expand commercial reach, and successful regulatory approvals that enable market access for differentiated products.
The principal investment risks are clinical and regulatory failure, the need for additional financing to advance development, and competitive pressure in the specialty pharmaceutical sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -24.21M | -29.15M | -0.16M | 0.92M | 2.68M |
| Minority interest | 0.04M | 0.06M | -0.22M | -0.22M | - |
| Net income | -24.96M | -29.15M | -0.94M | 1.48M | 2.12M |
| Selling general administrative | 6.91M | 18.71M | 1.15M | - | - |
| Gross profit | - | - | -1.37M | -3.33M | -1.56M |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | - | - |
| Ebit | - | -19.87M | -1.61M | 0.92M | 2.68M |
| Ebitda | -24.22M | -19.87M | -1.61M | -3.33M | -0.96M |
| Depreciation and amortization | - | 0.00M | 0.00M | - | - |
| Non operating income net other | - | - | 5.92M | 4.25M | 3.64M |
| Operating income | -24.22M | -19.87M | -1.61M | -3.33M | -0.96M |
| Other operating expenses | 24.22M | 19.87M | 1.61M | 3.33M | 0.96M |
| Interest expense | 0.11M | 1.30M | 1.00M | 0.00M | 0.00M |
| Tax provision | - | - | 0.24M | 0.56M | 0.55M |
| Interest income | 0.11M | 0.62M | 0.94M | 4.25M | 3.64M |
| Net interest income | -4.98M | -5.08M | -1.00M | - | - |
| Income tax expense | 0.75M | -0.00M | 0.78M | -0.56M | -0.55M |
| Total revenue | 2.52M | 3.53M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 24.22M | 19.87M | 1.61M | 3.33M | -0.60M |
| Cost of revenue | - | - | 1.37M | 3.33M | 1.56M |
| Total other income expense net | 0.01M | -9.28M | 1.45M | 4.25M | 3.64M |
| Net income from continuing ops | -24.21M | -29.15M | 4.31M | 0.37M | 2.12M |
| Net income applicable to common shares | -25.09M | -29.89M | 4.31M | 0.37M | 2.12M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2.71M | 5.89M | 16.42M | 0.35M | 196.51M |
| Other current assets | 1.17M | 2.15M | 3.40M | 0.15M | 0.14M |
| Total liab | 3.36M | 9.91M | 24.58M | 7.01M | 10.34M |
| Total stockholder equity | -0.65M | -4.03M | -8.16M | -6.44M | 5.00M |
| Other current liab | 0.54M | 2.25M | 3.43M | 0.86M | 2.77M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 181.17M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Retained earnings | -121.56M | -110.93M | -85.85M | -55.96M | 2.46M |
| Other liab | - | - | 3.65M | - | - |
| Other assets | - | 0.59M | 0.75M | 0.00M | 0.01M |
| Cash | 1.12M | 3.15M | 12.26M | 0.19M | 1.06M |
| Cash and equivalents | - | 3.15M | 12.26M | - | - |
| Total current liabilities | 3.33M | 9.46M | 16.48M | 7.01M | 2.77M |
| Current deferred revenue | - | - | - | 0.16M | - |
| Net debt | -0.27M | 1.26M | 0.48M | 4.08M | -1.06M |
| Short term debt | 0.85M | 4.27M | 12.75M | 4.27M | 0.00M |
| Short long term debt | 0.85M | 4.27M | 12.75M | 4.25M | - |
| Short long term debt total | 0.85M | 4.41M | 12.75M | 4.27M | 0.57M |
| Other stockholder equity | 120.91M | 106.90M | 77.69M | 49.52M | -178.63M |
| Property plant equipment | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total current assets | 2.29M | 5.30M | 15.66M | 0.35M | 1.20M |
| Net tangible assets | - | - | -7.88M | -1.21M | 186.17M |
| Short term investments | - | - | - | 12.63M | 195.31M |
| Net receivables | 0.10M | 0.28M | 0.44M | - | 0.17M |
| Long term debt | - | 0.14M | 4.44M | 0.79M | 0.57M |
| Inventory | -0.10M | -0.28M | -0.44M | - | - |
| Accounts payable | 1.94M | 2.94M | 0.30M | 1.72M | 2.77M |
| Common stock total equity | - | - | - | 0.05M | 0.00M |
| Retained earnings total equity | - | - | - | -1.21M | 2.46M |
| Non currrent assets other | 0.42M | 0.56M | -24720.25M | 0.00M | 195.31M |
| Non current assets total | 0.42M | 0.59M | 0.75M | 0.00M | 195.31M |
| Capital lease obligations | 0.00M | 0.03M | 0.02M | 0.03M | - |
| Long term debt total | - | 0.14M | 4.44M | 0.79M | 0.57M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 0.00M | - | 183.40M | 11.85M | - |
| Change to liabilities | - | -1.42M | 0.79M | 2.37M | 0.31M |
| Total cashflows from investing activities | 0.00M | - | 183.40M | 11.85M | 0.84M |
| Net borrowings | - | 13.91M | 1.23M | 0.57M | -0.03M |
| Total cash from financing activities | 8.77M | 20.31M | 1.10M | -11.03M | -0.03M |
| Change to operating activities | - | 0.56M | -1.17M | 1.40M | - |
| Net income | -24.21M | -29.15M | -0.16M | 0.37M | 2.12M |
| Change in cash | -9.12M | 12.07M | -0.15M | -0.60M | -0.43M |
| Begin period cash flow | 12.26M | 0.19M | 0.34M | 1.66M | 2.09M |
| End period cash flow | 3.15M | 12.26M | 0.19M | 1.06M | 1.66M |
| Total cash from operating activities | -17.89M | -8.24M | -1.25M | -1.42M | -1.24M |
| Issuance of capital stock | 3.78M | 6.63M | 0.00M | - | - |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Other cashflows from investing activities | 0.00M | - | 183.40M | 11.85M | 0.84M |
| Dividends paid | 0.91M | 803140.00M | - | - | - |
| Change to account receivables | - | -0.44M | 0.17M | -0.17M | - |
| Sale purchase of stock | 3.78M | 803140.00M | -184.78M | 11.58M | 0.00M |
| Other cashflows from financing activities | 7.30M | 14.15M | 1.10M | -11.03M | -0.03M |
| Change to netincome | - | 20.22M | -2.13M | -0.00M | -0.01M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Cash flows other operating | - | - | -4.06M | -4.16M | -3.67M |
| Cash and cash equivalents changes | - | - | -1.01M | -0.60M | -0.43M |
| Change in working capital | 5.48M | -1.30M | 0.19M | 2.34M | 0.32M |
| Stock based compensation | 1.07M | 0.12M | 0.18M | - | - |
| Other non cash items | -0.23M | 7.49M | 1.00M | -4.13M | -3.68M |
| Free cash flow | -17.89M | -8.24M | -1.25M | -1.42M | -1.24M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ENSC Ensysce Biosciences Inc |
-0.02 3.88% |
0.42 | - | - | 2.45 | 1.68 | -0.51 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. D. Lynn Kirkpatrick Ph.D. | Pres, CEO & Director | 1957 |
| Mr. David C. Humphrey CPA | CFO, Sec. & Treasurer | 1968 |
| Mr. Geoffrey Birkett | Chief Commercial Officer | 1962 |
| Dr. Jeffrey Millard Ph.d. | Chief Operating Officer | 1975 |
| Mr. Richard Wright M.B.A., MSE | Chief Bus. Officer | 1972 |
| Dr. William K. Schmidt Ph.D. | Chairman of Clinical Advisory Board & Chief Medical Officer | 1951 |
| Dr. Linda Pestano Ph.D. | Chief Devel. Officer | 1969 |
| Dr. D. Lynn Kirkpatrick Ph.D. | President, CEO & Director | 1957 |
| Mr. David C. Humphrey CPA | CFO, Secretary & Treasurer | 1969 |
| Mr. Geoffrey Birkett | Chief Commercial Officer | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...